Mithat ERENUS, Meltem UYGUR, Pınar YÖRÜK, Fatih DURMUŞOĞLU

the impact of women’s health initiative study on initiation and continuation of hormone therapy in a tertiary menopause unıt in Turkey

Amaç:Women’s Health Initiative (WHI) çalışmasının yayınlanmasının takiben hormon tedavisinin (HT)sürdürülmesi veya kesilmesine olan etkisini incelemek. Materyal ve Metod: Çalışma Temmuz 2002 ile Temmuz 2005 tarihleri arasında 816 postmenopozal kadın ile gerçekleştirildi. Hastalara sosyo-demografik özellikleri, HT kullanım bilgileri, WHI çalışması hakkında bilgiler soruldu. Bulgular: Kadınların ortalama yaşları 49,3±3,6 ve cevap oranları %54,7 idi. Katılımcıların %22,1'i HT almakta iken, %77,9'i HT kullanmamaktaydı. Kadınların üniversite mezunu, lise, ortaokul ve ilkokul mezunu olanları sırasıyla 131, 99, 60, 157 şeklinde idi. İlkokul mezunlarında HT kullanım oranı %25,üniversite mezunlarında %20 olması tedavinin eğitim durumundan etkilenmediğini göstermekte idi. 2002 yılının ikinci yarısında HT başlama oranı 18,6%, 2003'te % 30,5 şeklinde olup 2004 yılında %21,5'e, 2005 yılında %20,9 oranına geriledi. WHI çalışmasından sonra HT başlanan kadınlarda tedaviye devam oranı %41'di. Sonuç: Çalışmamız WHI sonuçlarının menopoz ünitemize HT devamı ve kesilmesi üzerine etkide bulunduğunu göstermektedir. WHI hakkında bilginin en çok medyadan veya doktorlardan elde edildiği ve HT devamı veya kesilmesi üzerine belirgin etkisi olduğunu saptandı.

Türkiyede tersiyer bir menopoz merkezinde women’s health initiative çalışmasının hormon tedavisi devamı veya kesilmesine olan etkisi

Objective: To determine the initiation and continuation rate of hormone therapy (HT) following publication of Women’s Health Initiative (WHI) study. Methods: A survey was performed to 816 postmenopausal women between July 2002 and July 2005. Questions included sociodemographic characteristics, determinants of HT use knowledge and source of information regarding the WHI study. Results: The average age was 49,3+3,6 years. Among the participants 22,1% were using HT whereas 77,9% were not on HT. Of the women; 131, 99, 60, 157 were graduated from university, high school, middle and primary school respectively. HT usage was 25% among primary school and 20% among university graduates, which appeared to be not affected by educational level. The rate of starting HT use was 18,6% in the second half of 2002. Initiation of HT was 30,5% in 2003, than decreased to 21,5% in 2004 and 20,9% in 2005. Among women whom HT was initiated after WHI the continuation rate was 41%. Conclusion: Our survey showed the negative impact of WHI findings on both about the initiation and continuation of HT in our menopause unit in Turkey. Information was mainly obtained by media or physician, may well have an important impact on continuation or discontinuationof HT.

PDF

___

1) Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in United States. Ann Intern Med. 1999;130:545-53
2) Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173:982-90
3) Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16
4) Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9
5) Gardy D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37
6) Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
7) Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
8) Beral V, Banks E, Reeves G. Evidence from randomized trials on the long term effects of hormone replacement therapy. Lancet 2002;360:942-44
9) Tattersall MH. Risks and benefits of postmenopausal combined hormone replacement therapy. Med J Aust 2002;177:173-4
10) Gorman C, Park A. The truth about hormones. Time. July 22,2002; Health and medicine section.
11) LeBanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and metanalysis. JAMA 2001;285:1489-99
12) Travers C, O’Neill SM, Khoo SK, King R. Hormones down under: hormone therapy use after the Women’s Health Initiative. Aust N Z J Obstet Gynaecol 2006; 46(4):330-5
13) Clanget C, Hinke V, Lange S, et al. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. Exp Clin Endocrinol Diabetes 2005;113(9):529-33
14) Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-50
15) Leung KY, Ling M, Tang GW. Use of hormone replacement therapy in the Hong Kong public health sector after the Women’s Health Initiative trial. Maturitas 2005;52(3-4):277-85
16) Blümel JE, Castelo-Branco C, Chedraui PA, et al. Patient’s and clinician’s attitudes after the Women’s Health Initiative study. Menopause 2005;11(1):57-61
17) Heitmann C, Greiser E, Dören M. The impact of the Women’s Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 2005;12(4):405-11
18) Karakoç B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998;5(2):102-6
19) Erenus M, Karakoc B, Gurler A. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 2001;4:228-34
20) North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of the North American Menopause Society. Menopause 2004;11(1):11-33
21) Hoffmann M, Hammar M, Kjellgren KI, et al. Changes in women’s attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 2005;16;52(1):11-17
22) Haas JS et al. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140(3):184-8
23) Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy. A population-based study. J Gen Intern Med 2005;20(11):1026-31
24) Ettinger B, Grady D, Tosteson AN, et al. Effect of the Women’s Health Initiative on women’s decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102(6):1225-1232